Document is current

Article History

Received: 20 January 2025

Accepted: 24 May 2025

First Online: 26 June 2025

Disclosure

: Tasuku Furube, Hirofumi Kawakubo, Kazuhiro Noma, Naoaki Maeda, Hiroyuki Daiko, Koshiro Ishiyama, Koji Otsuka, Yutaka Kishimoto, Kazuo Koyanagi, Kohei Tajima, Yuta Matsukawa, and Satoru Matsuda have no conflicts of interest or financial ties to disclose. Yuko Kitagawa reports grants and personal fees from Asahi Kasei Pharma Corporation; grants, personal fees, and others from Onopharmaceutical Co., Ltd.; grants and personal fees from Otsuka Pharmaceutical Factory, Inc.; grants and personal fees from Nippon Covidien Inc.; grants, personal fees, and others from Taihopharmaceutical Co., Ltd; grants, personal fees, and others from Chugai Pharmaceutical Co., Ltd.; grants and personal fees from Kaken Pharmaceutical Co., Ltd.; personal fees from AstraZeneca K.K.; personal fees from Ethicon Inc.; personal fees from Olympus Corporation; personal fees from Shionogi & Co., Ltd.; personal fees from Bristol-Myers Squibb K.K.; personal fees from MSD K.K.; personal fees from Smith & Nephew KK; personal fees from Aska Pharmaceutical Co., Ltd.; personal fees from Miyarisan Pharmaceutical Co., Ltd.; personal fees from Toray Industries, Inc.; personal fees from Daiichi Sankyo Co., Ltd.; personal fees from Chugai Foundation for Innovative Drug Discovery Science; personal fees from Nippon Kayaku Co., Ltd.; grants from Yakult Honsha Co., Ltd.; grants from Tsumura & Co.; grants from Sumitomo Pharma Co., Ltd.; grants and personal fees from EA Pharma Co., Ltd.; grants from Eisai Co., Ltd.; grants from Kyowa Kirin Co., Ltd.; grants from Medicon Inc.; grants from Takeda Pharmaceutical Co., Ltd.; grants from Teijin Pharma Limited; and personal fees from Intuitive Surgical G.K., outside the submitted work. Yuko Kitagawa and Yusuke Maeda have equity for Direava Inc. Masashi Takeuchi is a Chief Executive Officer for Direava Inc.